NeoGenomics, Inc. Form 8-K Summary
Business Context and Reporting Period
NeoGenomics, Inc. (NEO) filed this Current Report on Form 8-K on June 16, 2026, regarding a material definitive agreement and other events. The company is a Nevada corporation headquartered in Fort Myers, Florida, with common stock trading on The Nasdaq Stock Market.
Key Financial Metrics and Capital Structure
- New Debt Issuance: Completed an offering of $316.25 million in aggregate principal amount of 0.75% Convertible Senior Notes due 2032. This includes $275.0 million in Initial Notes and $41.25 million in Additional Notes following the exercise of an option by initial purchasers.
- Debt Repayment: Repurchased approximately $276.0 million in aggregate principal amount of existing 0.25% convertible senior notes due 2028 for a total cost of approximately $263.19 million (including accrued interest).
- Equity Repurchase: Entered into transactions to repurchase up to $25.0 million of common stock from certain purchasers of the new Notes at $10.49 per share.
- Derivatives: Entered into capped call transactions with a cap price of $20.98 per share, costing approximately $28.7 million of the net proceeds from the new Notes.
- Stock Price: The last reported sale price of common stock on June 16, 2026, was $10.49 per share.
Material Changes and Transaction Details
The filing details a significant refinancing event where the company extended its debt maturity profile while reducing near-term obligations.
- Convertible Notes Terms: The new 2032 Notes bear interest at 0.75% per annum, payable semiannually starting January 1, 2027. The initial conversion price is approximately $14.16 per share (a 35.0% premium to the June 16, 2026 price). The company may not redeem the Notes prior to July 6, 2029, except for a "Cleanup Redemption."
- Refinancing Impact: The repurchase of the 2028 notes was funded concurrently with the new issuance. The company also terminated portions of the capped call transactions associated with the repurchased 2028 notes.
- Dilution Management: The capped call transactions are designed to reduce potential dilution upon conversion of the new Notes and offset cash payments in excess of the principal amount, subject to the $20.98 cap price.
Guidance, Risks, and Contingencies
This filing does not contain updated financial guidance or management commentary on future operating performance. Key risks and contingencies include:
- Conversion Risk: Up to 30,147,733 shares of common stock may be issued upon conversion of the Notes, subject to anti-dilution adjustments.
- Redemption Conditions: The company's ability to redeem the Notes prior to maturity is contingent on the stock price trading at 130% of the conversion price for a specified period.
- Unregistered Securities: Shares issuable upon conversion have not been registered under the Securities Act and may not be sold in the U.S. absent registration or an exemption.
Investor Verification Checklist
- Verify the exact amount of net proceeds retained after the $28.7 million cost of capped call transactions and the $25.0 million stock repurchase.
- Confirm the impact of the $263.19 million repurchase cost on the company's current cash position and liquidity.
- Review the specific terms of the "Cleanup Redemption" and the conditions required for Optional Redemption after July 6, 2029.
- Monitor the stock price relative to the $14.16 conversion price and the $20.98 cap price to assess potential dilution or cash settlement scenarios.
- Check subsequent filings for the registration status of shares issuable upon conversion.